Skip to main content
Company profile
Cybin Inc. logo

Cybin Inc.

Pipeline3 assets

  • HLP0035-HT2A (and other serotonin receptors) / Deuterated NSA (oral) / Mental Health
    Adjunctive treatment of major depressive disorder (MDD)Phase 3Dosing underway (PARADIGM program); FDA Breakthrough Therapy DesignationUnited StatesEuropeAustralia
  • HLP004Serotonin receptors / Deuterated NSA (intramuscular) / Mental Health
    Generalized anxiety disorder (GAD)Phase 2Positive topline results reportedUnited States
  • HLP005NSA (phenethylamines and tryptamines) / Mental Health
    CNS disordersPreclinical

Latest news24 items

All news

Helus Pharma Announces Completion of Legal Name Change

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company’s legal name

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the

Presentation / Abstract • Phase 1/2Psych Congress poster presentation Tue, Sep 15, 2026

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of guiding pharmaceutical companies through late-stage clinical development and

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4 2026 1,2 HLP003 previously granted Breakthrough

Enrollment • Phase 3Enrollment milestone Fri, Dec 19, 2025

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ NSAs ”), is pleased to announce that it

Helus Pharma™ Announces US$50 Million Underwritten Offering

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ NSAs ”), is pleased to announce the

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale

Enrollment • Phase 3Enrollment milestone Wed, Sep 17, 2025

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP)

Cybin Inc. • Endpoint Arena